Deals channel feed – Endpoints News

Deals channel feed

Right as it gets a date with FDA, Forma offloads IDH1 inhibitor to Rigel

3 years ago

Who's afraid of the FTC? CSL gets its regulatory ducks lined up for $11.7B M&A deal

3 years ago

With some neuro targets in mind, AbbVie gets Sosei's drug discovery engine churning again

3 years ago

Under pressure from advocates, ViiV strikes a deal to make its long-acting HIV injectable more accessible

3 years ago

Cash-strapped biotech flips ex-MedImmune anti-inflammatory drug for $15M cash

3 years ago

Ipsen jumps into the TCR space, teaming with startup helmed by former Merck KGaA cancer chief

3 years ago

What can Merck afford to buy now? ‘ANYTHING’ it wants

3 years ago

Labcorp is spinning out its clinical development unit in major shakeup

3 years ago

More deals ahead for Bristol Myers? CEO Giovanni Caforio touts 'size agnostic' BD strategy

3 years ago

Versant and AbCellera go deeper on antibodies, pushing forward a trio of stealth companies

3 years ago

A year after netting Takeda partnership, small molecule startup arms itself with some new cash

3 years ago

Merck's ADC hunt continues with second deal for China biotech Kelun

3 years ago

Tonix scraps Covid-19 licensing deal after just three months — shares spike

3 years ago

Ginkgo Bioworks acquires struggling synbio rival Zymergen in $300M all-stock deal

3 years ago

NewAmsterdam's bid to revive Amgen cardio drug heads to Nasdaq in Frazier SPAC deal

3 years ago

Low-profile startup stakes its claim to Sanofi's siRNA platform in wake of setbacks

3 years ago

Sosei Heptares partners with a UK-based cancer research organization to bring its drug to trial

3 years ago

OrbiMed-backed Silverback, three months after hacking the pipeline, reverse-merges with small allergy biotech

3 years ago

Vertex taps Verve for gene editing pact — buying a chunk of shares — as Sek Kathiresan steers base editing into clinic

3 years ago

Bristol Myers vets tie up another all-stock deal, lining up clinical-stage oncology pipeline

3 years ago

Safety scare cleared and early data in hand, Ultragenyx dishes out $75M to buy rare disease partner

3 years ago

Following Luxturna and slate of eye disease approvals, Roche adds another ophthalmology partner for AAV gene therapies

3 years ago

BlackRock joins Andrew Lo's risk analysis firm to search for odds-on biotech bets in turbulent times

3 years ago

Nestlé puts down $40M, kicks off deal with gut microbiome specialist to fight food allergies

3 years ago

First page Previous page 53 54 555657 58 59 Next page Last page